Epigenomics AG announced that several German laboratories will start offering laboratory-developed colorectal cancer blood tests based on Epigenomics’ proprietary biomarker mSEPT9 on October 1st, 2009.
Read More
What laboratories should be doing now to prepare for the conversions to ICD-10 and X12 5010.
Read More
Point-of-care testing aims to improve health care with quick turnaround times.
Read MoreEpigenomics AG, a cancer molecular diagnostics company, today announced that it signed a non-exclusive licensing agreement for its proprietary DNA methylation biomarker Septin 9 (mSEPT9) with Salt Lake City, Utah. based ARUP Laboratories Inc.
Read MoreBeckman Coulter Inc announces the creation of Beckman Coulter Genomics. The new company, which combines Agencourt Bioscience and the newly acquired Cogenics, offers researchers a single genomic services resource with expanded global capabilities.
Read More